GW Pharmaceuticals reports loss despite success of CBD-based drug

CBD drug manufacturer GW Pharmaceuticals saw a significant net loss in the last quarter, despite growth and sales of its cannabis-derived pharmaceutical drugs going to plan.

The company reported a loss of $71.9m for the quarter ending 31st December 2018, compared with $61.8m for the same quarter in 2017.


Restricted content. Do you want to read more?